The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Financial support is being provided as a grant from the Government of India
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
Subscribe To Our Newsletter & Stay Updated
